In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death ligand 1 (PD-L1) ≥1% (primary end point) or <1% (prespecified descriptive analysis). We report results with minimum 4 years’ follow-up.
Researchers looked at lung tissue from 28 COPD patients and 15 smokers who underwent surgery for suspected or confirmed lung cancer.
The Clinical Year in Review series at the ATS 2025 International Conference concluded on Wednesday, May 21, with a discussion of impactful studies spanning pulmonary…
Dr. Gonzalo Labarca of Pontificia Universidad Catolica de Chile is the first recipient from Chile to receive an ATS grant.
Deep dives into the latest research and therapeutic advances in bronchiectasis, interstitial lung disease, lung transplant, and pulmonary infections were the focus of the third…
The Clinical Year in Review series continued at ATS 2025 San Francisco with an examination of studies with clinical practice implications, and a closer look…
Martin Kang, PhD, of the Medical University of South Carolina, is this year’s recipient of the ATS/ALA Commemorative 120th Anniversary Joint Research…
The first session of the Clinical Year in Review series began with an exploration of evolving concepts and practice-changing studies in asthma, interventional pulmonary medicine,…
The ATS is offering multiple ATS 2025 Conference Highlights packages for those interested in continuing their educational experience beyond the conference. Don’t miss the opportunity…
A podcast with Shoshana Zha, MD and Jeff Tarnow, RCP, RRT from University of California, San Francisco discussing airway clearance therapy for patients with bronchiectasis…
